| Structure |
Catalog |
Product Name |
CAS |
E3 Ligase |
Target |
Inquiry |
 |
BPL-202693 |
N1-(2-(2,6-Dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)-N8-hydroxyoctanediamide |
2233579-08-1 |
CRBN |
HDAC1
HDAC3
HDAC6 |
Inquiry |
|
Molecular Weight: 430.46
Molecular Formula: C21H26N4O6
Density: 1.385±0.06 g/cm3
Description: It is an HDAC degrader with a CRBN E3 ligase ligand.
|
 |
BPL-202694 |
N1-(2-(2,6-Dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)-N9-hydroxynonanediamide |
2758388-36-0 |
CRBN |
HDAC1
HDAC3
HDAC6 |
Inquiry |
|
Molecular Weight: 444.49
Molecular Formula: C22H28N4O6
Density: 1.358±0.06 g/cm3
Description: It is an HDAC degrader with a CRBN E3 ligase ligand.
|
 |
BPL-202695 |
N1-(2-(2,6-Dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)-N10-hydroxydecanediamide |
2758388-37-1 |
CRBN |
HDAC1
HDAC3
HDAC6 |
Inquiry |
|
Molecular Weight: 458.52
Molecular Formula: C23H30N4O6
Density: 1.333±0.06 g/cm3
Description: It is an HDAC degrader with a CRBN E3 ligase ligand.
|
 |
BPL-202696 |
N1-(2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)-N8-hydroxyoctanediamide |
2758388-38-2 |
CRBN |
HDAC1
HDAC3
HDAC6 |
Inquiry |
|
Molecular Weight: 444.44
Molecular Formula: C21H24N4O7
Density: 1.446±0.06 g/cm3
Description: It is an HDAC degrader with a CRBN E3 ligase ligand.
|
 |
BPL-202697 |
6-(3-(2-(2,6-Dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)ureido)-N-hydroxyhexanamide |
2758388-47-3 |
CRBN |
HDAC1
HDAC3
HDAC6 |
Inquiry |
|
Molecular Weight: 431.45
Molecular Formula: C20H25N5O6
Density: 1.423±0.06 g/cm3
Description: It is an HDAC degrader with a CRBN E3 ligase ligand.
|
 |
BPL-202698 |
7-(3-(2-(2,6-Dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)ureido)-N-hydroxyheptanamide |
2758388-48-4 |
CRBN |
HDAC1
HDAC3
HDAC6 |
Inquiry |
|
Molecular Weight: 445.48
Molecular Formula: C21H27N5O6
Density: 1.393±0.06 g/cm3
Description: It is an HDAC degrader with a CRBN E3 ligase ligand.
|
 |
BPL-202699 |
9-(3-(2-(2,6-Dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)ureido)-N-hydroxynonanamide |
2758388-49-5 |
CRBN |
HDAC1
HDAC3
HDAC6 |
Inquiry |
|
Molecular Weight: 473.53
Molecular Formula: C23H31N5O6
Density: 1.342±0.06 g/cm3
Description: It is an HDAC degrader with a CRBN E3 ligase ligand.
|
 |
BPL-202700 |
6-(3-(2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)ureido)-N-hydroxyhexanamide |
2758388-50-8 |
CRBN |
HDAC1
HDAC3
HDAC6 |
Inquiry |
|
Molecular Weight: 445.43
Molecular Formula: C20H23N5O7
Density: 1.486±0.06 g/cm3
Description: It is an HDAC degrader with a CRBN E3 ligase ligand.
|
 |
BPL-202701 |
N-(2-Aminophenyl)-4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzamide |
2758388-53-1 |
CRBN |
HDAC1
HDAC3
HDAC6 |
Inquiry |
|
Molecular Weight: 484.51
Molecular Formula: C27H24N4O5
Boiling Point: 743.4±60.0°C at 760 Torr
Density: 1.420±0.06 g/cm3
Description: It is an HDAC degrader with a CRBN E3 ligase ligand.
|
 |
BPL-202702 |
N-(2-Aminophenyl)-4-(((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)methyl)benzamide |
2758388-54-2 |
CRBN |
HDAC1
HDAC3
HDAC6 |
Inquiry |
|
Molecular Weight: 498.49
Molecular Formula: C27H22N4O6
Boiling Point: 725.6±60.0°C at 760 Torr
Density: 1.476±0.06 g/cm3
Description: It is an HDAC degrader with a CRBN E3 ligase ligand.
|
 |
BPL-202703 |
4-(((2-(2,6-Dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)-N-hydroxybenzamide |
2758388-57-5 |
CRBN |
HDAC1
HDAC3
HDAC6 |
Inquiry |
|
Molecular Weight: 409.40
Molecular Formula: C21H19N3O6
Density: 1.455±0.06 g/cm3
Description: It is an HDAC degrader with a CRBN E3 ligase ligand.
|
 |
BPL-202704 |
4-(((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)methyl)-N-hydroxybenzamide |
2758388-58-6 |
CRBN |
HDAC1
HDAC3
HDAC6 |
Inquiry |
|
Molecular Weight: 423.38
Molecular Formula: C21H17N3O7
Density: 1.524±0.06 g/cm3
Description: It is an HDAC degrader with a CRBN E3 ligase ligand.
|
 |
BPL-202705 |
C004019 |
2417159-57-8 |
VHL |
Tau |
Inquiry |
|
Molecular Weight: 1035.31
Molecular Formula: C49H70N12O9S2
Density: 1.300±0.06 g/cm3
Description: It is a small molecule PROTAC that selectively promotes tau clearance to improve cognitive functions in Alzheimer's like models.
|
![(S)-2-Chloro-N-(4-(2-((2-(2-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)ethoxy)ethyl)amino)-2-oxoethyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-N-(2-cyanoethyl)acetamide](https://resource.bocsci.com/structure/2763548-62-3.gif) |
BPL-202706 |
(S)-2-Chloro-N-(4-(2-((2-(2-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)ethoxy)ethyl)amino)-2-oxoethyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-N-(2-cyanoethyl)acetamide |
2763548-62-3 |
FEM1B |
BRD4 |
Inquiry |
|
Molecular Weight: 806.78
Molecular Formula: C38H41Cl2N9O5S
Density: 1.44±0.1 g/cm3
Description: It is a PROTAC linking EN106 to the BET bromodomain inhibitor JQ1, resulting in the degradation of BRD4.
|
![(S)-2-Chloro-N-(4-(2-((5-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)pentyl)amino)-2-oxoethyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-N-(2-cyanoethyl)acetamide](https://resource.bocsci.com/structure/2709040-03-7.gif) |
BPL-202707 |
(S)-2-Chloro-N-(4-(2-((5-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)pentyl)amino)-2-oxoethyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-N-(2-cyanoethyl)acetamide |
2709040-03-7 |
FEM1B |
BRD4 |
Inquiry |
|
Molecular Weight: 804.81
Molecular Formula: C39H43Cl2N9O4S
Density: 1.41±0.1 g/cm3
Description: It is a PROTAC linking EN106 to the BET bromodomain inhibitor JQ1, resulting in the degradation of BRD4.
|
![(S)-2-Chloro-N-(4-(14-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-2,13-dioxo-6,9-dioxa-3,12-diazatetradecyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-N-(2-cyanoethyl)acetamide](https://resource.bocsci.com/structure/2763548-65-6.gif) |
BPL-202708 |
(S)-2-Chloro-N-(4-(14-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-2,13-dioxo-6,9-dioxa-3,12-diazatetradecyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-N-(2-cyanoethyl)acetamide |
2763548-65-6 |
FEM1B |
BRD4 |
Inquiry |
|
Molecular Weight: 850.83
Molecular Formula: C40H45Cl2N9O6S
Density: 1.42±0.1 g/cm3
Description: It is a PROTAC linking EN106 to the BET bromodomain inhibitor JQ1, resulting in the degradation of BRD4.
|
![(S)-2-Chloro-N-(4-(17-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-2,16-dioxo-6,9,12-trioxa-3,15-diazaheptadecyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-N-(2-cyanoethyl)acetamide](https://resource.bocsci.com/structure/2763548-67-8.gif) |
BPL-202709 |
(S)-2-Chloro-N-(4-(17-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-2,16-dioxo-6,9,12-trioxa-3,15-diazaheptadecyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-N-(2-cyanoethyl)acetamide |
2763548-67-8 |
FEM1B |
BRD4 |
Inquiry |
|
Molecular Weight: 894.88
Molecular Formula: C42H49Cl2N9O7S
Density: 1.40±0.1 g/cm3
Description: It is a PROTAC linking EN106 to the BET bromodomain inhibitor JQ1, resulting in the degradation of BRD4.
|
![(S)-2-Chloro-N-(4-(20-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-2,19-dioxo-6,9,12,15-tetraoxa-3,18-diazaicosyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-N-(2-cyanoethyl)acetamide](https://resource.bocsci.com/structure/2763548-69-0.gif) |
BPL-202710 |
(S)-2-Chloro-N-(4-(20-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-2,19-dioxo-6,9,12,15-tetraoxa-3,18-diazaicosyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-N-(2-cyanoethyl)acetamide |
2763548-69-0 |
FEM1B |
BRD4 |
Inquiry |
|
Molecular Weight: 938.94
Molecular Formula: C44H53Cl2N9O8S
Density: 1.39±0.1 g/cm3
Description: It is a PROTAC linking EN106 to the BET bromodomain inhibitor JQ1, resulting in the degradation of BRD4.
|
![N-(2-Chloro-6-methylphenyl)-2-((6-(4-(5-(2-(7-(2-chloro-N-(2-cyanoethyl)acetamido)-2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl)acetamido)pentyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide](https://resource.bocsci.com/structure/2763548-75-8.gif) |
BPL-202711 |
N-(2-Chloro-6-methylphenyl)-2-((6-(4-(5-(2-(7-(2-chloro-N-(2-cyanoethyl)acetamido)-2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl)acetamido)pentyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide |
2763548-75-8 |
FEM1B |
BCR-ABL |
Inquiry |
|
Molecular Weight: 848.86
Molecular Formula: C40H47Cl2N11O4S
Density: 1.366±0.06 g/cm3
Description: It is a PROTAC linking EN106 to the kinase inhibitor dasatinib, resulting in the degradation of BCR-ABL.
|
![N-(2-Chloro-6-methylphenyl)-2-((6-(4-(1-(7-(2-chloro-N-(2-cyanoethyl)acetamido)-2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl)-2-oxo-6,9,12-trioxa-3-azatetradecan-14-yl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide](https://resource.bocsci.com/structure/2763548-77-0.gif) |
BPL-202712 |
N-(2-Chloro-6-methylphenyl)-2-((6-(4-(1-(7-(2-chloro-N-(2-cyanoethyl)acetamido)-2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl)-2-oxo-6,9,12-trioxa-3-azatetradecan-14-yl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide |
2763548-77-0 |
FEM1B |
BCR-ABL |
Inquiry |
|
Molecular Weight: 938.94
Molecular Formula: C43H53Cl2N11O7S
Density: 1.361±0.06 g/cm3
Description: It is a PROTAC linking EN106 to the kinase inhibitor dasatinib, resulting in the degradation of BCR-ABL.
|
